Abstract
The positron emission tomography (PET) tracer [18F]MNI-659, selective for phosphodiesterase 10A (PDE10A), is a promising tool to assess an early biomarker for Huntington’s disease (HD). In this study we investigated [18F]MNI-659 uptake in the Q175 mouse model of HD. Given the focal striatal distribution of PDE10A as well as the striatal atrophy occurring in HD, the spatial normalization approach applied during the processing could sensibly affect the accuracy of the regional quantification. We compared the use of a magnetic resonance images (MRI) template based on individual MRI over a PET and CT templates for regional quantification and spatial normalization of [18F]MNI-659 PET images. We performed [18F]MNI-659 PET imaging in six months old heterozygous (HET) Q175 mice and wild-type (WT) littermates, followed by X-ray computed tomography (CT) scan. In the same week, individual T2-weighted MRI were acquired. Spatial normalization and regional quantification of the PET/CT images was performed on MRI, [18F]MNI-659 PET, or CT template and compared to binding potential (BPND) using volumes manually delineated on the individual MR images. Striatal volume was significantly reduced in HET mice (-7.7%, p<0.0001) compared to WT littermates. [18F]MNI-659 BPND in striatum of HET animals was significantly reduced (p<0.0001) when compared to WT littermates using all three templates. However, BPND values were significantly higher for HET mice using the PET template compared to the MRI and CT ones (p<0.0001), with an overestimation at lower activities. On the other hand, the CT template spatial normalization introduced larger variability reducing the effect size. The PET and CT template-based approaches resulted in a lower accuracy in BPND quantification with consequent decrease in the detectability of disease effect. This study demonstrates that for [18F]MNI-659 brain PET imaging in mice the use of an MRI-based spatial normalization is recommended to achieve accurate quantification and fully exploit the detectability of disease effect.
Highlights
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder characterized by progressive decline in motor function and cognition, and development of psychiatric symptoms [1]
Given the focal striatal distribution of Phosphodiesterase 10A (PDE10A) as well as the striatal atrophy occurring in HD, we evaluated different approaches of spatial normalization of the positron emission tomography (PET) data in order to determine which one provides optimal detectability of the disease effect: the first was based on a magnetic resonance images (MRI) template generated using the individual MR images, a second on a PET template, and a third using the computed tomography (CT) images
We prospectively evaluated the BPND values after MRI, PET, and CT template-based spatial normalization of HET mice and WT littermates
Summary
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder characterized by progressive decline in motor function and cognition, and development of psychiatric symptoms [1]. The main neuropathological feature of HD is the loss of GABAergic medium spiny neurons (MSNs), which represent about 80–90% of striatal neurons [3]. This results in progressive striatal atrophy, followed by cortical degeneration in some patients [4]. HD-related PDE10A decrease at early disease stage has been confirmed by several in vivo studies both in mouse models of HD [11,12,13] and patients with HD [14, 15]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
